# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTRODUCTION</td>
<td>2</td>
</tr>
<tr>
<td>WELCOME</td>
<td>3</td>
</tr>
<tr>
<td>LITERATURE</td>
<td>4</td>
</tr>
<tr>
<td>This month's selected article</td>
<td>4</td>
</tr>
<tr>
<td>Immunogenicity</td>
<td>6</td>
</tr>
<tr>
<td>Methods</td>
<td>6</td>
</tr>
<tr>
<td>Animal models</td>
<td>7</td>
</tr>
<tr>
<td>Biomarkers</td>
<td>7</td>
</tr>
<tr>
<td>Systemic Lupus Erythematosus</td>
<td>8</td>
</tr>
<tr>
<td>Rheumatoid Arthritis</td>
<td>8</td>
</tr>
<tr>
<td>Inflammatory Bowel Diseases</td>
<td>9</td>
</tr>
<tr>
<td>Multiple Sclerosis</td>
<td>10</td>
</tr>
<tr>
<td>Hemophilia</td>
<td>11</td>
</tr>
<tr>
<td>Basic immunology</td>
<td>12</td>
</tr>
<tr>
<td>Opinions/Commentaries/Across diseases reviews</td>
<td>12</td>
</tr>
<tr>
<td>REGULATION</td>
<td>13</td>
</tr>
<tr>
<td>EMA</td>
<td>13</td>
</tr>
</tbody>
</table>
INTRODUCTION

A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for a number of serious conditions. Yet sometimes these medicines trigger a response from the patient’s immune system, which can decrease the effectiveness of the drug or cause severe side effects.

The aim of the IMI-founded ABIRISK project “Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Re to Minimize the Risk”, is to shed new light on the factors behind this immune response. The project, which represents the first concerted effort to solve this problem, officially kicked off March 1st, 2012. ABIRISK project will aid in the creation of new, safer biopharmaceuticals (BPs) and also generate tools to determine how individual patients are likely to respond to them both in clinical trials and after release to the market.

The ABIRISK consortium (presently made up of thirty-five partners, twenty-four of which are academic institutions, nine are EFPIA member companies and two are small and medium enterprises, with thirteen countries represented), has been designed to meet all of these requirements in order to target three types of disorders: Hemophilia A, Multiple sclerosis and Inflammatory diseases: inflammatory rheumatisms (including rheumatoid arthritis) and inflammatory bowel diseases.

ABIRISK Project will collect data both retrospectively from patients suffering from various types of diseases and treated with various BPs at European centers with a high level of experience in clinical research and will prospectively recruit additional patients in dedicated studies during the 5 years of this program. Guidelines and Standard Operating Protocols for the study of anti-drug immunization will be established and used to standardize the collection of prospective data from these patients.

ABIRISK Project thus represents a unique opportunity to create an interdisciplinary task force of clinical centers especially designed to study immune responses against biopharmaceuticals.
Dear Reader,

We would like to welcome you to the March 2015 issue of the ABIRISK Scientific Newsletter. The Scientific Newsletter gives you a monthly update on the most relevant literature related to ABIRISK topics published around the globe, both inside and outside ABIRISK consortium.

This month, we chose to draw your attention to a paper published by N. Gupta et al in Science Translational Medicine, in which they describe a novel strategy to prevent anti-drug immune responses in Hemophilia A upon induction of central and peripheral tolerance during fetal life.

In addition, you will find in this issue some regulatory news on biopharmaceuticals.

We look forward to your visit on ABIRISK website for more information and updates on the program.

Enjoy reading!

Best wishes

The ABIRISK management team
LITERATURE

This month's selected article

Advert immune responses may occur against some protein therapeutics. This is the case in patients with genetic disorders such as hemophilia A, hemophilia B, Willebrand disease or Pompe disease, when they receive exogenous factor VIII, factor IX, Willebrand factor or alpha-glucosidase. The development of neutralizing antibodies to Protein Therapeutics represents a major clinical complication and a problem of public health. In such pathologies, in utero induction of immune tolerance to Protein Therapeutics would represent a major step to improve the clinical management of the patients as well as their quality of life and reduce associated societal costs.

The article published by N Gupta et al describes a novel strategy to prevent anti-drug immune responses upon induction of central and peripheral tolerance during fetal life. The strategy exploits the fact that maternal immunoglobulins G (IgG) are transferred to the circulation of the fetus through the placenta via the neonatal Fc receptor. The results demonstrate that the materno-fetal transfer of a protein fused to the Fc fragment of the IgG generates specific and long-lasting tolerance in newborn mice. Using transgenic mice expressing a monoclonal T-cell receptor specific for hemagglutinin, the authors demonstrate that tolerance is associated with an increase in central and peripheral regulatory T cells specific for the administered antigen. The scientists then bring the proof-of-concept for the validity of their approach in the murine pre-clinical model of severe hemophilia A, a rare hemorrhagic disorder linked to the X chromosome and resulting from the absence of functional pro-coagulation factor VIII. The transplacental transfer of factor VIII fragments fused to the IgG Fc fragment reduced in a drastic manner the neutralizing anti-factor VIII immune response on the offspring upon treatment with therapeutic FVIII later in life. Tolerance was mediated by the induction of factor VIII-specific regulatory T cells.

Hemophilia is the most appropriate disorder to envisage translation of these observations in patients. Indeed, the birth of a hemophilic baby may be anticipated based on familial history of hemophilia A, and confirmed by simple and antenatal genetic tests. Besides, the risk for a hemophilia A patient to develop a neutralizing anti-
factor VIII immune response (up to 30% of the patients) may be predicted at the time of diagnosis of hemophilia A in a rather faithful manner. Further, a fusion FVIII-Fc was recently released in the US and should reach the European market in the coming year.

Immunogenicity

The challenging definition of naïve patient for biological drug use.
Biggioggero M, Danova M, Genovese U, Locatelli F, Meroni PL, Pane F, Scaglione F.
Autoimmun Rev. 2015 Jan 31

Significance of low level infliximab in the absence of anti-infliximab antibodies.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
Oldenburg J, Lacroix-Desmazes S, Lillicrap D.
Haematologica. 2015 Feb;100(2):149-156.

Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses.
Reipert BM.

Toward optimal therapy for inhibitors in hemophilia.
Kempton CL, Meeks SL.

Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.
Xu Z, Davis HM, Zhou H.

Comparative immunogenicity assessment: a critical consideration for biosimilar development.
Liu PM, Zou L, Sadhu C, Shen WD, Nock S.
Bioanalysis. 2015 Feb;7(3):373-81

Methods

Feasibility of immuno-PCR technology platforms as an ultrasensitive tool for the detection of anti-drug antibodies.
Jani D, Savino E, Goyal J.
Animal models

**Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model.**
Häusler D, Nessler S, Kruse N, Brück W, Metz I.

Biomarkers

**CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study.**
Marnetto F, Granieri L, Valentino P, Capobianco M, Pautasso M, Bertolotto A.

**IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis.**

**MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study.**
Brennan-Bourdon LM, De la Cruz-Mosso U, Reyes-Castillo Z, Martínez-Bonilla GE, Ramírez-Dueñas MG, Islas-Carbajal MC, Rincón-Sánchez AR, Salazar-Páramo M, Muñoz-Valle JF.

**Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis.**
Systemic Lupus Erythematosus

Responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM, Wittmann M, Edward S, Yuzaiul M, MacIver H, Pease CT, Goodfield M, Emery P.
Arthritis Rheumatol. 2015 Feb 23.

Normalization of CD4+ T cell metabolism reverses lupus.

Rheumatoid Arthritis

Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
Kostik MM, Dubko MF, Masalova VV, Snegireva LS, Kornishina TL, Chikova IA, Isupova EA, Kuchinskaya EM, Glebova NI, Buchinskaya NV, Kalashnikova OV, Chasnyk VG.

Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S.
J Rheumatol. 2015 Feb 15.

Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.
Smolen JS, Aletaha D.
Nat Rev Rheumatol. 2015 Feb 17.

One year in review: novelties in the treatment of rheumatoid arthritis.

The impact of biological therapy on regulatory T cells in rheumatoid arthritis.
Byng-Maddick R, Ehrenstein MR.
**Efficacy and safety of anti-IL-20 monoclonal antibody in patients with rheumatoid arthritis: A randomized phase 2a trial.**

**Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis.**

### Inflammatory Bowel Diseases

**Effectiveness and Safety of Immunomodulators with Anti-TNF Therapy in Crohn’s Disease.**

**Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.**

**Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.**

**Trough Concentrations of Infliximab Guide Dosing for Patients with Inflammatory Bowel Disease.**

**Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.**
Multiple Sclerosis

**IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.**

**Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.**

**Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.**
D’Amico E, Caserta C, Patti F.

**Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis.**
Hoy SM.
CNS Drugs. 2015 Feb 10.

**A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.**
Harari D, Orr I, Rotkopf R, Baranzini SE, Schreiber G.

**Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.**
D’Amico E, Caserta C, Patti F.

**Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis.**
Xie ZX, Zhang HL, Wu XJ, Zhu J, Ma DH, Jin T.
Mediators Inflamm. 2015;2015:513295.

**Emerging role of IL-16 in cytokine-mediated regulation of multiple sclerosis.**
Skundric DS, Cruikshank WW, Montgomery PC, Lisak RP, Tse HY.
Cytokine. 2015 Feb 18.
Multiple sclerosis: summary of NICE guidance.
Perry M, Swain S, Kemmis-Betty S, Cooper P; Guideline Development Group of the National Institute for Health and Care Excellence.
BMJ. 2014 Oct 8;349:g5701

Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Le Page E, Deburghgraeye V, Lester MA, Cardiet I, Leray E, Edan G.
J Neurol. 2015 Feb 21

The conundrum of interferon-β non-responsiveness in relapsing-remitting multiple sclerosis.
Huber AK, Duncker PC, Irani DN.
Cytokine. 2015 Feb 14.

Interleukin-10 but not transforming growth factor-β1 gene expression is up-regulated by vitamin D treatment in multiple sclerosis patients.
Farsani ZS, Behmanesh M, Sahraian MA.

Hemophilia

A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC.

Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM.
Haemophilia. 2015 Feb 16.

The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors.
Silveira AC, Santana MA, Ribeiro IG, Chaves DG, Martins-Filho OA.
BMC Hematol. 2015 Jan 16;15(1):1
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.

Basic immunology

Cutting Edge: Circulating Plasmablasts Induce the Differentiation of Human T Follicular Helper Cells via IL-6 Production.
Chavele KM, Merry E, Ehrenstein MR.

Opinions/Commentaries/Across diseases reviews

Biosimilars: the science of extrapolation.
Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK.

Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J, Kudrin A.
Immunotherapy. 2015 Feb;7(2):73-87.

Application of metabolomics in autoimmune diseases: Insight into biomarkers and pathology.
Kang J, Zhu L, Lu J, Zhang X.

Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases.
Siebert S, Tsoukas A, Robertson J, McInnes I.
Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J, Kudrin A.
Immunotherapy. 2015 Feb;7(2):73-87.

Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.
Xu Z, Davis HM, Zhou H.

Secukinumab: first global approval.
Sanford M, McKeage K.
Drugs. 2015 Feb;75(3):329-38.

REGULATION

EMA

Pending EC decision: Humira, adalimumab
Opinion date: 26-Feb-2015

Opinion/decision on a Paediatric Investigation Plan (PIP): Recombinant single-chain coagulation factor VIII
Therapeutic area: Haematology-Hemostaseology
Updated
February 2015

Work plan for the CHMP Biologics Working Party 2015
Updated
February 2015

Orphan designation: Recombinant human monoclonal antibody to human IL-1 beta of the IgG1/K class
Updated
February 2015
Human medicines European public assessment report (EPAR): Inflectra, infliximab
Revision: 6, Authorised
February 2015

Human medicines European public assessment report (EPAR): Simponi, golimumab
Revision: 20, Authorised
February 2015